Chenodeoxycholic Acid (CAS 474-25-9): Comprehensive User Guide
Table of Contents
1. Product Overview & Specifications
Chenodeoxycholic Acid (CDCA, CAS 474-25-9) is a primary bile acid synthesized from cholesterol in the liver. As a pharmaceutical-grade compound, it meets USP/EP standards for critical therapeutic and research applications.
| Parameter | Specification |
|---|---|
| CAS Number | 474-25-9 |
| Molecular Formula | C24H40O4 |
| Purity | ≥98% (HPLC) |
| Melting Point | 165-168°C |
| Solubility | Ethanol (50 mg/mL), DMSO (25 mg/mL) |
2. Key Applications & Use Cases
2.1 Therapeutic Applications
- Dissolution of cholesterol gallstones
- Treatment of cerebrotendinous xanthomatosis (CTX)
- Modulation of FXR nuclear receptors
2.2 Research Applications
- Studying bile acid metabolism pathways
- Investigation of apoptosis mechanisms
- Membrane permeability studies
3. Performance Comparison
| Property | CDCA | Cholic Acid | UDCA |
|---|---|---|---|
| Hydrophobicity Index | 0.89 | 0.65 | 0.72 |
| FXR Activation | High | Moderate | Low |
| Therapeutic Dose Range | 10-15 mg/kg/day | N/A | 8-12 mg/kg/day |
4. Industry-Specific Usage Scenarios
4.1 Pharmaceutical Manufacturing
Used as active ingredient in enteric-coated tablets for sustained release formulations.
4.2 Cell Culture Systems
Optimal concentration range: 50-100 μM for hepatocyte studies.
5. Client Success Stories
Case 1: European Pharma Innovator
Developed CTX treatment protocol using CDCA with 92% reduction in cholestanol levels.
Case 2: US Biotech Startup
Utilized CDCA in novel NASH drug development, achieving 40% FXR activation improvement.
6. Request Customized Solutions
Contact our technical team for formulation support or bulk orders:
Email: info@vivalr.com
Phone: (86) 15866781826



评论
目前还没有评论。